Variants in Pharmacokinetic Transporters and Glycemic Response to Metformin: A Metgen Meta‐Analysis
Year: 2017
Type: review
Abstract: Therapeutic response to metformin, a first-line drug for type 2 diabetes (T2D), is highly variable, in part likely due to genetic factors. To date, metformin pharmacogenetic studies have mainly focused on the impact of variants in metformin transporter genes, with inconsistent results. To clarify the significance of these variants in glycemic response to metformin in T2D, we performed a large-scale meta-analysis across the cohorts of the Metformin Genetics Consortium (MetGen). Nine candidate polymorphisms in five transporter genes (organic cation transporter [OCT]1, OCT2, multidrug and toxin extrusion transporter [MATE]1, MATE2-K, and OCTN1) were analyzed in up to 7,968 individuals. None of the variants showed a significant effect on metformin response in the primary analysis, or in the exploratory secondary analyses, when patients were stratified according to possible confounding genotypes or prescribed a daily dose of metformin. Our results suggest that candidate transporter gene variants have little contribution to variability in glycemic response to metformin in T2D.
DOI: 10.1002/cpt.567
Authors: T Dujic, K Zhou, SW Yee, N van Leeuwen, CE de Keyser, M Javorský, S Goswami, L Zaharenko, MM Hougaard Christensen, M Out, R Tavendale, M Kubo, MM Hedderson, AA van der Heijden, L Klimčáková, V Pirags, A Kooy, K Brøsen, J Klovins, S Semiz, I Tkáč, BH Stricker, CNA Palmer, LM 't Hart, KM Giacomini, ER Pearson
Institutions: University of Sarajevo, University of Dundee, University of California, San Francisco, Leiden University Medical Center, Dutch Health Care Inspectorate, Erasmus MC, University of Pavol Jozef Šafárik, Univerzitná Nemocnica Louisa Pasteura, Latvian Biomedical Research and Study Centre, Odense University Hospital, Treant Zorggroep, Ziekenhuis Bethesda, RIKEN Center for Integrative Medical Sciences, Kaiser Permanente, Kaiser Permanente Northern California, Amsterdam Public Health, Amsterdam UMC Location Vrije Universiteit Amsterdam, University of Southern Denmark, International University of Sarajevo
Language: English
Subfield: Pharmacology
Domain: Life Sciences
Open Access status: hybrid
Estimated APC paid: $1,844
Funders: Ellison Medical Foundation, Robert Wood Johnson Foundation, Wayne and Gladys Valley Foundation, Kaiser Permanente, Vanderbilt University, Wellcome Trust, European Federation of Pharmaceutical Industries and Associations, European Commission, European Foundation for the Study of Diabetes, ZonMw, Vedecká Grantová Agentúra MŠVVaŠ SR a SAV, Innovative Medicines Initiative, Ministarstvo Civilnih Poslova Bosne i Hercegovine, National Institutes of Health, Fonden til Lægevidenskabens Fremme, RIKEN, National Institute on Aging, National Institute of General Medical Sciences
Awards: DIabetes REsearCh on patient sTratification, G3207356259, G3529949959, A Resource for Genetic Epidemiology Research in Adult Health and Aging, G3725864416, G393177772, Pharmacogenomics of Membrane Transporters, G5702163051, Discovery of Pharmacogenomic Biomarkers for OATP1B1 and OATP1B3, Stratified medicine in Type 2 diabetes: Insights from the study of drug response., Pharmaceutical Sciences and Pharmacogenomics, G9000074218
OpenAlex ID: W2556453587
